The QualityStocks Daily Tuesday, June 12th, 2018

Today's Top 3 Investment Newsletters

Penny Pick Finders (GLMD) +151.29%

QualityStocks (SKVI) +35.11%

StreetInsider (RH) +30.55%

The QualityStocks Daily Stock List

QS Energy, Inc. (QSEP)

RedChip, InvestorsHub, Stockopedia, Equity Clock, Stockhouse, MarketWatch, Marketwired, StockInvest.us, The Street, and Small Cap Exclusive reported previously on QS Energy, Inc. (QSEP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

QS Energy, Inc. is a developer of integrated technology solutions for the energy industry. It develops and commercializes energy efficiency technologies, which help in meeting rising international energy demands, improving the economics of oil extraction and transport, and reducing greenhouse gas emissions. QS Energy’s Intellectual Property (IP) portfolio includes 48 domestic and worldwide patents and patents pending. These have undergone development in combination with, and exclusively licensed from, Temple University.

Established in 1998, QS Energy has its head office in Tomball, Texas. The Company’s shares trade on the OTC Markets Group’s OTCQB. The Company previously went by the name Save the World Air, Inc. It changed its name to QS Energy, Inc. in August of 2015.

The Company’s AOT™ (Applied Oil Technology) is a group of commercial crude oil pipeline flow assurance products designed to undergo installation at pipeline pump stations in the upstream, gathering, and also midstream sectors. AOT™ is an integrated system. It improves critical operational efficiencies for pipeline operators around the world.

QS Energy has its new strategic plan. The core mission of this plan is to hasten market adoption of its AOT™ technology.

AOT™ is an industrial hardware system. It is totally fabricated in the United States. AOT™ lowers the viscosity of unrefined oil employing low wattage electrical fields (electrorheology) to improve flow while in transit through pipelines.

AOT™ technology delivers performance that can be measured in each of the areas of importance in the movement hydrocarbon stream - from reservoir to the point of sale. QS Energy’s AOT™ stand-alone or supplemental pipeline solutions boost flow rates; lessen power consumption; optimize flow assurance; enhance pipeline integrity; and prevent bottlenecks.

The Company is now positioned to complete its development from research and development (R&D) to commercialization. All through 2017, QS Energy worked to improve the efficacy and efficiency of its AOT technology, executing a retrofit program underpinned by lessons learned while operating its equipment on midstream pipelines under commercial operating conditions.

In April of this year, QS Energy entered into a non-binding Letter Of Intent (LOI) with a second South American oil company to test crude oil samples and, subject to laboratory results, negotiate and execute binding demonstration project agreements. The customer operates capacity-constrained pipelines, producing very heavy crudes (approximately API 8°) with high levels of asphaltene.

At present, the customer is relying on a combination of heat and diluent techniques to maintain production. QS Energy states that based on laboratory tests on comparable crude oil samples, AOT should have a major impact.

In Asia, QS Energy is advancing on a potential demonstration project with an Asian oil company.  The project is proceeding, targeting demonstration project operations before year end.

Furthermore, QS Energy applied for federal and provincial grants in Canada related to pipeline efficiency and GHG emissions reductions programs.  The Company’s aim with the project is to supply partial funding of a demonstration project at a Canadian partner site, providing white paper data in support of commercialization and industry acceptance.

QS Energy, Inc. (QSEP), closed Tuesday's trading session at $0.1051, down 4.37%, on 67,283 volume with 16 trades. The average volume for the last 60 days is 85,216 and the stock's 52-week low/high is $0.0802/$0.32.

chart

Creative Medical Technology Holdings, Inc. (CELZ)

MarketWatch and OTC Markets reported on Creative Medical Technology Holdings, Inc. (CELZ), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Creative Medical Technology Holdings, Inc. (CMT) is a clinical stage stem cell company. Its concentration is on Urology and Neurology using stem cell treatments. Since 2011, CMT and its affiliate company, Creative Medical Health, Inc., have focused on regenerative medical solutions for unmet Urological and Neurological needs. The Company has a patent portfolio encompassing all treatments. Listed on the OTCQB, CMT is based in Phoenix, Arizona.

CMT has its StemSpine™ initiative. This is a treatment designed to reverse the affects of atherosclerosis, which is the underlying disease that causes disc degeneration. CMT’s solutions include Caverstem™ for Erectile Dysfunction (ED).

The Caverstem™ procedure uses a patient's own bone marrow derived stem cells to stimulate arterial, venous and smooth muscle regeneration. Caverstem™  is an outpatient procedure performed by urologists in their medical facilities. The Company is using a patient's own cells. It does not manipulate the stem cells via the use of chemicals, growth factors or expansion.

CMT (through its own research as well as collaborations with top academic institutions) has acquired a pioneering stem cell (Amniostem), and developed proprietary protocols. In addition, it has built a wide-ranging intellectual property (IP) portfolio, developed complete treatment offerings for erectile dysfunction (ED), and launched a 40-patient trial for ED at UCLA. Furthermore, the Company is making advances for treating stroke utilizing its newly acquired amniotic fluid-based stem cell.

Amniostem is Amniotic fluid derived stem cell. The Amniostem patent covers means to isolate, grow, and use amniotic fluid derived stem cells in a scalable and commercializable manner. Amniostem therapy is a practical protocol for producing therapeutic quality stem cells starting from a small (1-5 ml) amniocentesis sample. Amniostem cells do not require matching with the recipient, as one size fits all.

CMT has an exclusive rights agreement with UCLA for US patent application # 14/508763, covering the use of stem cells for the treatment of male infertility. Additionally, CMT has filed US patent application number #62319753, covering the treatment of female sexual dysfunction using stem cell and progenitor cell populations.

In October 2017, CMT announced completion of the safety data analysis on 20 patients with pharmacologically-resistant erectile dysfunction treated with the Company's patented CaverStem™ procedure. The trial was sponsored by CMT.

The trial was conducted at the University of California Los Angeles Harbor Hospital/LA Biomed under Institutional Review Board (IRB) approval. Additionally, an independent medical safety monitor was appointed to review the patient data for safety and feasibility of administering bone marrow derived stem cells into patients with erectile dysfunction.

This past December, Creative Medical Technology announced recruitment of leading urologists in the Southwestern U.S. to perform its patented Caverstem™  procedure to treat erectile dysfunction in patients who do not respond to currently available treatments.

Mr. Timothy Warbington, Creative Medical Technology Holdings’ President and Chief Executive Officer, said, "We are pleased to have received such enthusiasm from the Urology community in the first 30 days of commercialization and we anticipate similar responses as we expand our physician base throughout the United States."

Creative Medical Technology Holdings, Inc. (CELZ), closed Tuesday's trading session at $0.0197, up 4.79%, on 12,642,148 volume with 309 trades. The average volume for the last 60 days is 53,275,127 and the stock's 52-week low/high is $0.0021/$0.55.

chart

Kush Bottles, Inc. (KSHB)

Stock News Now, The Street, StreetAuthority Daily, CFN Media Group, Promotion Stock Secrets, and SmallCapVoice reported on Kush Bottles, Inc. (KSHB), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Kush Bottles, Inc. is a sales and distribution platform that offers packaging, supplies, vaporizers, accessories, and branding solutions for the regulated cannabis industry. The Company provides certified child-resistant and custom-branded solutions in all States that permit medical or recreational cannabis use. Kush Bottles is the only marijuana packaging company with numerous full-service facilities across the United States. The Company has its headquarters and California fulfillment center in Santa Ana, California.

Kush Bottles acquired CMP Wellness, LLC (Los Angeles, California) last year. CMP is a privately held distributor of vaporizers, cartridges, and accessories. The Company also acquired the web domain Roll-uh-Bowl.com. This is an online distribution platform for retail sales of collapsible and unbreakable medical-grade silicone water pipes.

Kush Bottles provides pop top bottles; child resistant exit, paper exit, and foil barrier bags; tubes; and polystyrene, polypropylene, or silicone containers to urban farmers, greenhouse growers, and medical and recreational cannabis dispensaries. The Company concentrates on providing the highest quality medical and food grade packaging. In addition, Kush Bottles concentrates on choosing products that are environmentally friendly and manufactured within the United States.

Kush Bottles now regularly services more than 4,000 legally operated medical and adult-use dispensaries, growers, and producers across North America, South America, and Europe. In addition, the Company has opened a new Product Development and Genomics Lab in San Diego, California to produce unique terpene formulations.

Kush Bottles has launched the marijuana industry's first online system. The system enables customers to design custom-branded packaging solutions. The tool makes it easier for customers to place orders. The expectation is that this will lead to a higher conversion rate and a better Return on Investment (ROI).

Kush Bottles has launched a Food and Drug Administration (FDA) compliant Kush Canister™ to safely and securely store cannabis products for resale purposes. The canister can fit just over one ounce of cannabis flower. The canister has a certified child resistant push-top to comply with regulations in the States that require child resistant packaging.

This month, Kush Bottles announced it was chosen by Future Farm Technologies, Inc. (FFRMF) to develop a set of customized packaging and comprehensive compliance solutions to support its expansion into new territories. Kush Bottles will support Future Farm's expansion. It will also provide branded packaging solutions to ensure Future Farm maintains compliance with State-level regulations at all times.

Future Farm is promptly expanding its footprint in the cannabis and hemp sectors across the nation. Its emphasis is on California, Massachusetts, Maine, Florida and Puerto Rico.

Also this month, Kush Bottles announced that it entered into a strategic partnership with a top cannabis ancillary fund, Merida Capital Partners. Kush has received a $6 million equity investment from Merida to speed up its near and long-term growth strategy. Kush Bottles’ plan is to use the proceeds to expand its product portfolio, build new distribution channels and penetrate new legalized markets.

Kush Bottles, Inc. (KSHB), closed Tuesday's trading session at $5.56, up 2.39%, on 644,955 volume with 1,371 trades. The average volume for the last 60 days is 425,236 and the stock's 52-week low/high is $1.81/$8.51.

chart

NXT Energy Solutions, Inc. (NSFDF)

Serious Traders, StockOoodles, SmarTrend Newsletters, Vantage Wire, and Streetwise Reports reported earlier on NXT Energy Solutions, Inc. (NSFDF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

NXT Energy Solutions, Inc. is a technology business established in 1994. The Company’s proprietary Stress Field Detection (SFD®) survey system uses quantum-scale sensors to detect gravity field perturbations in an airborne survey method, which can be used onshore and offshore to remotely identify areas with exploration potential for traps and reservoirs. OTCQB-listed, NXT Energy Solutions is based in Calgary, Alberta.

The Company provides its clients with an effective and reliable method to reduce time, costs, as well as risks related to exploration. The SFD® survey system enables its clients to focus their hydrocarbon exploration decisions regarding land commitments, data acquisition expenditures, and prospect prioritization on areas with the greatest potential.

NXT Energy Solutions’ inventive geophysical service is for the upstream oil & gas industry. SFD® is environmentally friendly. It is unaffected by ground security issues or difficult terrain. SFD® is an airborne tool. It provides information on areas favorable to fluid entrapment in the sedimentary column. The SFD® survey is complementary to existing geophysical methods, particularly seismic programs.

SFD®, in pre-seismic applications, can produce high-potential prospect leads in large underexplored regions. In post-seismic applications, SFD® can prioritize seismic prospects based on their reservoir potentials.

NXT Energy Solutions announced this past January the first international patent of the Stress Field Detection (SFD®) Technology and the development of a new generation of sensors that will enhance the Company’s ability to provide higher quality survey results. NXT is actively negotiating commercial contracts for the application of its proprietary SFD® oil & gas exploration method with governments, national oil companies, as well as other industry participants.

Q1 operating highlights for NXT Energy Solutions include NXT Management restarting marketing for SFD® survey contracts and multi-client data sales across South East Asia, China and Latin America. Additionally, SHINE Quests FZC, an appointed representative of NXT, is working on the financing needed for a large scale infrastructure and resource development within the Mannar Basin in Sri Lanka that would include a commitment to conduct an SFD® survey.

Furthermore, Generation Resource Discoveries (GRD), an appointed representative of NXT, entered into an MOU (Memorandum of Understanding) with the Government of Aceh to carry out a geophysical survey within the Aceh Basin in Indonesia and proposes to enter into contract discussions with NXT Energy Solutions in association with the performance of that survey upon securing permits and third party financing.

In addition, NXT engaged two new sales agents for SFD® surveys in South America centered in Mexico and Peru to take advantage of its experience and past success in the region.

NXT Energy Solutions, Inc. (NSFDF), closed Tuesday's trading session at $0.6958, down 5.45%, on 6,725 volume with 4 trades. The average volume for the last 60 days is 10,392 and the stock's 52-week low/high is $0.317/$1.05.

chart

BioVie, Inc. (BIVI)

Penny Stock Tweets, Wealth Insider Alert, InvestorsHub, Morningstar, and MarketWatch reported earlier on BioVie, Inc. (BIVI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

BioVie, Inc. concentrates on the discovery, development, and commercialization of unique drug therapies for liver disease. At present, the clinical-stage Company is focusing on commercializing BIV201. This is a novel approach to the treatment of ascites due to chronic liver cirrhosis. BioVie has its head office in Beverly, Massachusetts. The Company lists on the OTC Markets’ OTCQB.

BioVie states that BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, NASH, and alcoholism. The US Patent and Trademark Office (USPTO) issued US Patent No. 9,655,945 covering BioVie’s new drug candidate BIV201.

BIV201 has Orphan Drug designation for the most common of these complications, ascites, which represents a significant unmet medical need. The Food and Drug Administration (FDA) has never approved any drug specifically for treating ascites. In addition to patient suffering, U.S. treatment costs for liver cirrhosis, including ascites and other complications, are estimated at greater than $4 billion annually.

BIV201 is a continuous infusion of the peptide terlipressin, first undergoing development for the treatment of refractory ascites. Terlipressin, dosed differently, is approved in about 40 nations for other complications of liver cirrhosis coming up from a similar disease pathway. Terlipressin is not available in the U.S.

BioVie announced in April of 2017 that it received notice from the FDA that the planned Phase 2a clinical trial of its new drug candidate BIV201 could begin. This was based on BioVie’s IND to conduct a study in patients with refractory or intractable ascites due to advanced liver cirrhosis.

In addition, BioVie was notified by the USPTO that its application for a core patent covering the use of BIV201 to reduce ascites formation in ambulatory patients was authorized. BioVie also announced in April of 2017 the signing of a Cooperative Research and Development Agreement (CRADA). This is to conduct a Phase 2a clinical trial of BIV201 in patients with refractory or intractable ascites because of advanced liver cirrhosis.

BioVie announced in December of 2017 that the FDA granted Fast Track designation for BIV201 (continuous infusion terlipressin), the Company's patented Orphan drug candidate. BIV201 is now undergoing evaluation for the treatment of refractory ascites due to liver cirrhosis in a mid-stage (Phase 2a) US clinical trial.

Recently, BioVie announced that it achieved 50 percent enrolments of the patients in its open-label Phase 2a clinical study of BIV201 (continuous infusion terlipressin) for treating refractory ascites due to advanced liver cirrhosis.

Penny Markham, PhD, BioVie Chief Scientist, stated, “The patients we are targeting for BIV201 therapy are desperately ill and experience a miserable quality of life. Absent liver transplantation, their outcomes are very poor. We are pleased to be working on developing a novel drug candidate that could potentially improve their future.”

BioVie, Inc. (BIVI), closed Tuesday's trading session at $0.0489, up 28.68%, on 35,600 volume with 7 trades. The average volume for the last 60 days is 102,393 and the stock's 52-week low/high is $0.012/$0.35.

chart

Humanigen, Inc. (HGEN)

OTC Markets, AmigoBulls, TradingView, Investopedia, InvestorsHub, Barchart, Investors Hangout, and Financial Times reported on Humanigen, Inc. (HGEN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Humanigen, Inc. concentrates on advancing medicines for patients with neglected and rare diseases by way of unique, accelerated business models. Lead compounds in the Company’s portfolio include the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab. Derived from its Humaneered® platform, lenzilumab and ifabotuzumab are lead compounds in the portfolio of monoclonal antibodies with first-in-class mechanisms. Humanigen is based in Brisbane, California. The Company lists on the OTCQB.

Humanigen pursues innovative science to develop its proprietary monoclonal antibodies for immunotherapy and oncology treatments. Lenzilumab has potential for treatment of different rare diseases. These include hematologic cancers such as chronic myelomonocytic leukemia (CMML), and juvenile myelomonocytic leukemia (JMML).

Lenzilumab is a Humaneered® recombinant monoclonal antibody. It neutralizes soluble granulocyte-macrophage colony-stimulating factor (GM-CSF), which is a critical cytokine that drives the growth of certain hematologic malignancies.

The other key asset in Humanigen’s monoclonal antibody portfolio, ifabotuzumab, has been dosed in the first patient in an investigator-sponsored Phase 0/1 radio-labeled imaging trial in glioblastoma multiforme (GBM). GBM is a particularly aggressive and deadly brain cancer.

Ifabotuzumab is a first-in-class, monoclonal antibody. It targets the EphA3 receptor tyrosine kinase created employing the Company’s proprietary Humaneered® technology.

Humanigen announced in March of this year that it completed patient enrollment in the continuing Phase 1 trial of lenzilumab in patients with previously treated chronic myelomonocytic leukemia (CMML).

The design of the Phase 1, multi-center, open-label, dose-escalation trial is to evaluate the maximum tolerated dose, safety and tolerability of single-agent lenzilumab in 12 patients with CMML who are relapsed, refractory to, or intolerant to standard-of-care treatments. The trial will also provide additional data on pharmacokinetics and pharmacodynamics.

Last month, Lupagen announced the intent to explore the development of a bedside, point-of-care delivered CAR-T therapy with Humanigen. Lupagen is a medical device company. It is developing first-in-class cell and gene therapy delivery technologies for CAR-T, gene editing and immunotherapy products. Lupagen and Humanigen are planning work to investigate the potential of a bedside CAR-T therapy created from Humanigen's Ifabotuzumab. Lupagen, Inc. is a privately held early stage medical device company.

Humanigen, Inc. (HGEN), closed Tuesday's trading session at $0.555, down 21.83%, on 1,020 volume with 4 trades. The average volume for the last 60 days is 5,689 and the stock's 52-week low/high is $0.125/$2.60.

chart

Stealth Technologies, Inc. (STTH)

NetworkNewsWire and RedChip reported previously on Stealth Technologies, Inc. (STTH), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Stealth Technologies, Inc. is a technology business listed on the OTC Markets Group’s OTCQB. The Company previously went by the name Excelsis Investments, Inc. It changed its name to Stealth Technologies, Inc. in July 2016. Stealth Technologies engages in identifying and capitalizing on technology and associated markets. The Company produces products for personal and financial protection.

Incorporated in 2010, Stealth Technologies has its corporate office in Largo, Florida. It became public through a reverse merger in 2012.

Moreover, Stealth Technologies announced in March of this year the completion of five new products. Currently, these products are staged in a large direct response retailer's quality assurance and legal department. They are under final review to ensure that marketing claims associated with each product are accurate when measured against actual performance levels of each product, and that assurance and inventory is satisfactory and has met all quality control factors. Stealth Technologies’ strategic initiative is to expand its product footprint across varied industries and distributors.

The Company has developed a group of products to protect against "electronic pickpockets," emergency response latency, credit fraud protection, and cell phone data protection. Its initial product to market is the Stealth Card.

The design of the Stealth Card is to protect the Radio-Frequency Identification (RFID) chip in a consumer's credit card from electronic stealing or pickpocketing, which uses a smartphone, credit card reader, or RFID antenna to remotely access data stored on the consumer's Smartchip. Stealth Card renders the chipped information invisible to intrusion.

The Stealth Card is a 100 percent USA product. The Stealth Card is manufactured from Stealth Technologies’ laboratory and research/development facility in West Virginia to its manufacturing facility in Massachusetts.

Development for the Stealth Card started in 2012. This is when Company Founder and Chief Executive Officer (CEO), President, and Director, Mr. Brian McFadden, observed the worldwide shift towards smart chip card technology to transmit and process credit card/debit card transactions. With Europe and Asia already making the transition away from the magnetic strip to smart chip cards, Mr. McFadden believed the United States market would need to follow suit.

To use the Stealth Card, a person places a Stealth Card in their wallet, pocket, change purse or anywhere they carry their credit cards. One card can protect up to 12 cards in a wallet. The card can be physically placed anywhere in a wallet or pocket.

The card does not need to be in the front or back of one’s wallet. The Stealth Card provides effective protection irrespective of where it’s placed in relation to one’s credit cards.

In December 2016, Stealth Technologies announced the development of the 911 Help Now Generation II Product. The 911 Help Now product provides a direct two-way voice connection to emergency service providers. The 911 Help Now pendent works by pressing the Help Now button and then a person is connected.

Stealth Technologies has a number of other products under development. The Company is exploring potential military applications of its proprietary technologies.

Along with the Stealth Card and the 911 Help Now Generation II Product, Stealth Technologies’ portfolio includes Data Secure Plus, which is new to market. Its portfolio also includes Stealth Mobile.

Stealth Technologies, Inc. (STTH), closed Tuesday's trading session at $0.078, up 34.48%, on 17,821 volume with 1 trade. The average volume for the last 60 days is 18,337 and the stock's 52-week low/high is $0.013/$0.60.

chart

Molori Energy, Inc. (MOLOF)

Stockhouse, Streetwise Reports, InvestorsHub, and MarketWatch reported on Molori Energy, Inc. (MOLOF), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Molori Energy, Inc. has current operations in the Texas Panhandle West Field. The Company’s operating team based in Borger, Texas has wide-ranging experience in the oil and gas industry in the Texas Panhandle. Molori Energy's business model is to deliver sustainable growth in shareholder value through focusing on exploiting its existing reserves, commercializing and developing discoveries, and pursuing selective acquisitions.

An oil and gas production enterprise, Molori Energy is based in Vancouver, British Columbia. The Company formerly went by the name Taipan Resources, Inc. It changed its name to Molori Energy Inc. in January 2017.

Molori’s strategy has been to engage in low-risk well reactivations in the Texas Panhandle to produce steady cash flows. More than 60 wells have been reactivated so far. These are producing from the prolific Brown Dolomite formation.

The Company owns a 25 percent Working Interest (WI) in certain leases situated in the bifurcated Texas panhandle, operated by its Texas-based partner Ponderosa Energy, LLC. Molori Energy has 165 producing (PDP) wells and an inventory of roughly 202 non-producing wells (PDNP) for a total of 367 wells. Molori is working to RTP (Return to Production) the PDNP wells through performing simple re-works or re-completions.

Molori and Ponderosa Energy have identified a development opportunity in the Red Cave formation. The formation is common throughout its leases at a shallower depth of 2,100’ to 2,300’. Improved fracing technologies and completion techniques have shown the Red Cave to be an economic development target.

Molori Energy announced this past February a commercial oil discovery on its acreage in Moore County, Texas. The "Thompson 23-1R" well, operated by the Company, is a northern step-out well drilled in December 2017. The Thompson 23-1R well is directly north of the active development area of Adams Affiliates.

Recently, Molori Energy announced that it signed an LOI (Letter of Intent) to purchase a 100 percent WI of which Molori will be the operator of record in an additional roughly 5,100 gross acres of land in Moore, Potter, and Carson Counties, north Texas.

With this agreement, Molori Energy is to hold a 100 percent WI in the leases, some of which border lands where Adams Affiliates of Tulsa, Oklahoma is now developing oil and gas production from the Red Cave formation. The roughly 5,100 acres are presently held by production (HBP). They contain a 75 percent NRI (Net Royalty Interest).

Molori Energy, Inc. (MOLOF), closed Tuesday's trading session at $0.195, down 4.88%, on 17,148 volume with 9 trades. The average volume for the last 60 days is 43,099 and the stock's 52-week low/high is $0.175/$0.5066.

chart

Tautachrome, Inc. (TTCM)

Stockhouse, Penny Stock Tweets, TheOTCReporter, Barchart, MarketWatch, 4-Traders, and InvestorsHub reported on Tautachrome, Inc. (TTCM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Tautachrome, Inc. is an emerging growth company in the developing digital imagery technology sector. It is a developer of software applications for trustable and engageable digital pictures and videos. The Company’s main priority is developing its branded KlickZie platform. An Internet technology development business, Tautachrome is based in Oro Valley, Arizona.

The KlickZie platform will turn smartphones into trusted imagers. This means the pictures and videos they capture can be verified as original, untampered, and un-photoshopped. Furthermore, the KlickZie platform creates imagery that is interactive and engageable.

KlickZie is an image verification service for smartphones. It brings trust back to digital imagery. KlickZie also turns the smartphone into a reliable image source. Smartphone users download KlickZie’s free software to take their pictures and videos.

The KlickZie platform will serve as the world’s first imagery-based social website network. Through clicking or tapping on a KlickZie'd image, users can communicate with the image's author or others currently looking at the image, in an engaging way.

KlickZie pictures and videos are invisibly marked, stored in the KlickZie cloud, and guaranteed free from manipulation. The cloud will certify the authenticity of any KlickZie picture or video.

Tautachrome is establishing a development team of providers to develop a blockchain based cryptocurrency ecosystem with a cryptotoken designated “KLK”. It will be the currency of the KlickZie community globally. This past April, Tautachrome announced the issuance of its wholly-owned US Patent number 9,928,352, a key KlickZie technology patent, which aims to turn smartphone imagery into “touch-to-comm” portals of social interaction. The Company’s touch-to-comm patent is the second of six KlickZie patents pending to issue. The other four patents pending encompass code protection inside the smartphone and additional touch-to-com claims.

Additionally, in April, Tautachrome announced the addition of Mr. Aasim Saied to its Board of Directors. The Tautachrome team met Mr. Saied at its attendance at the “TokenFest” networking event in San Francisco, California in March 2018. Mr. Saied is an inventor, entrepreneur and futurist. He developed the Projector Phone technology and a variety of other products and services.

Tautachrome, Inc. (TTCM), closed Tuesday's trading session at $0.0085, up 4.94%, on 374,288 volume with 7 trades. The average volume for the last 60 days is 315,902 and the stock's 52-week low/high is $0.0024/$0.028.

chart

Cardax, Inc. (CDXI)

Zacks reported earlier on Cardax, Inc. (CDXI), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Cardax, Inc. is a development stage life sciences enterprise based in Honolulu, Hawaii. The Company dedicates primarily all its efforts to developing consumer health and pharmaceutical products that it believes will provide many of the anti-inflammatory benefits of steroids or NSAIDS through targeting many of the same inflammatory pathways and mediators, but with exceptional safety profiles. Cardax’s shares trade on the OTC Markets Group’s OTCQB.

The Company’s Intellectual Property (IP) portfolio consists of 21 issued patents. These include 14 in the United States and seven in China, India, Japan, and Hong Kong. Cardax said it will continue to seek appropriate patent protection for its products in the U.S. and other selected nations. Cardax’s patents will expire between 2023 and 2028, subject to patent extensions. The Company has five patent applications pending in Europe, Canada, and Brazil.

Cardax is preparing proprietary nature-identical products and related derivatives by way of total synthesis to provide scalable, pure, and economical therapies for diseases where inflammation and oxidative stress are strongly implicated. This includes, but is not limited to, osteoarthritis, rheumatoid arthritis, dyslipidemia, metabolic disease, diabetes, cardiovascular disease, hepatitis, cognitive decline, macular degeneration, and prostate disease.

Cardax’s initial main emphasis is its astaxanthin technologies. Astaxanthin is a strong and safe naturally occurring anti-inflammatory and anti-oxidant without the adverse side effects characteristic of anti-inflammatory treatments using steroids or NSAIDS (including immune system suppression, liver damage, cardiovascular disease risk, and gastrointestinal bleeding). The safety and efficacy of Cardax’s product candidates have not been directly evaluated in clinical trials or confirmed by the Food and Drug Administration (FDA).

In 2014, Cardax and Capsugel entered into a Collaboration Agreement for the joint development of astaxanthin products for the consumer health market utilizing Capsugel’s proprietary lipid multiparticulate (LMP) formulation technology. Capsugel’s LMP technology encapsulates dissolved or suspended active ingredients into spherical lipid matrix particles. The expectation is it will boost the oral bioavailability of astaxanthin.

Furthermore, BASF has exclusively licensed rights from Cardax. This is to develop and commercialize nature-identical astaxanthin in consumer health products. BASF will pay Cardax royalties on future net sales of such products. Moreover, Cardax can purchase nature-identical astaxanthin from BASF for consumer health applications.

Cardax’ ZanthoSyn® is the Company’s first product to help consumers safely address their inflammatory health. Cardax says that ZanthoSyn® is a physician recommended anti-inflammatory supplement for health and longevity, which features astaxanthin with optimal absorption and purity. ZanthoSyn® contains astaxanthin, which is Generally Recognized as Safe (GRAS) according to FDA regulations.

In October 2017, Cardax announced that it entered into a mutual exclusivity agreement with General Nutrition Corporation (GNC) for ZanthoSyn. The exclusivity agreement builds on Cardax’s previously announced national rollout of ZanthoSyn across GNC's greater than 3,200 U.S. corporate stores.

It now designates GNC as the exclusive "brick-and-mortar" retailer of ZanthoSyn in the U.S. The exclusivity agreement encompasses the use of ZanthoSyn as a human dietary supplement, with an initial term of two years and provides for automatic renewals. GNC is the leading specialty retailer of health, wellness, as well as performance products.

Cardax, Inc. (CDXI), closed Tuesday's trading session at $0.25, up 8.70%, on 5,281 volume with 4 trades. The average volume for the last 60 days is 33,761 and the stock's 52-week low/high is $0.07/$0.59.

chart

Bluestone Resources, Inc. (BBSRF)

OTC Markets, MarketWatch, 4-Traders, Barchart, Dividend Investor, Investors Hangout, OtcStockWatch, and Penny Stock Hub reported on Bluestone Resources, Inc. (BBSRF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Bluestone Resources, Inc. focuses on advancing its 100 percent owned Cerro Blanco Gold and Mita Geothermal Projects in Guatemala. The Cerro Blanco Project is a classic hot springs-related, low sulphidation gold-silver deposit. On February 14, 2018, the Company announced that its common shares commenced trading on the OTCQB Venture Marketplace. A mineral exploration and development company, Bluestone Resources has its headquarters in Vancouver, British Columbia.

The Cerro Blanco Project economics and updated mineral resource estimate for Cerro Blanco indicates a strong project with an expected nine-year mine life producing 952,000 ounces of gold and 3,141,000 ounces of silver. Initial capital expenditures estimated in the Preliminary Economic Assessment (PEA) to fund construction and commissioning is estimated at US$170.8 million with all in sustaining cash estimated to be US$490 per ounce of gold produced.

The permitted Mita Geothermal Project is located adjacent to Bluestone’s Cerro Blanco Gold Project in Guatemala. It is in southeast Guatemala, about 160 kilometers by road from the capital, Guatemala City. The Mita geothermal resource was discovered in the late 1990’s during gold exploration in southeastern Guatemala.

Bluestone Resources controls the required surface rights for the Mita Geothermal Project and the Cerro Blanco Project. The Cerro Blanco Gold Project is not dependent on the Mita Geothermal Project. Nonetheless, Company Management’s belief is that there are potential synergies between the two that enhance the economics of the Cerro Blanco Gold Project beyond what was outlined in the PEA.

In late May, Bluestone Resources announced more positive drill results from its resource definition drill program at the Cerro Blanco Gold project in Guatemala. Highlights include the following core intercepts representing true widths of the veins.

These include 17.2 g/t Au and 94.9 g/t Ag over 7.0 meters (UGCB18-86); and
32.7 g/t Au and 79.6 g/t Ag over 8.3 meters (UGCB18-86).

These additionally include 16.7 g/t Au and 105.4 g/t Ag over 15.0 meters (UGCB18-89); and 14.3 g/t Au and 68.5 g/t Ag over 9.3 meters (UGCB18-89).

Bluestone Resources, Inc. (BBSRF), closed Tuesday's trading session at $1.0897, even for the day. The average volume for the last 60 days is 1,645 and the stock's 52-week low/high is $0.8593/$1.35.

chart

The QualityStocks Company Corner

Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX)

The QualityStocks Daily Newsletter would like to spotlight Foresight Autonomous Holdings Ltd. (FRSX).

Foresight Autonomous Holdings Ltd. (Nasdaq and TASE: FRSX), an innovator in automotive vision systems, announced today the first sale of a prototype of its breakthrough QuadSightTM quad-camera vision system targeted for the semi-autonomous and autonomous vehicle market, designated to allow near 100% obstacle detection under any weather and lighting conditions. The first system was ordered by a truck division of a large European vehicle manufacturer in order to evaluate the system and its performance on the manufacturer’s trucks. Revenue from the system sale is expected to total tens of thousands of dollars.

Foresight Autonomous Holdings Ltd. (NASDAQ: FRSX) (TASE: FRSX), founded in 2015 and headquartered in Israel, is a technological innovator in automotive vision systems and driver assistance technology. Through its wholly owned subsidiary, Foresight Automotive Ltd., Foresight is engaged in the design, development and commercialization of stereo/quad-camera vision systems and V2X cellular-based solutions for the automotive industry based on 3D video analysis, advanced algorithms for image processing and sensor fusion. The company’s powerful and patented stereoscopic technology is derived from field-proven technology that has been deployed throughout the world for almost two decades.

Foresight’s innovative autonomous driving solutions are based on mature, proprietary stereoscopic image technology that uses two synchronized cameras to mimic human depth perception and produce a three-dimensional image. This 3D image can anticipate possible collisions with other vehicles, cyclists, pedestrians and other obstacles. The technology provides highly accurate real-time alerts about the vehicle’s surroundings while in motion. The systems are designed to improve driving safety by enabling highly accurate and reliable threat detection while ensuring the lowest rates of false alerts.

The company’s patents provide IP protection for its robust and proven proprietary stereoscopic technology, which was developed using the security technology of Foresight’s major shareholder, Magna B.S.P.

Foresight has developed three main products:

  • QuadSight™. This breakthrough detection system sets the bar for autonomous vehicle vision. It features nearly 100 percent obstacle detection with almost zero false alerts and operates optimally under all weather and lighting conditions, including darkness, rain, fog, haze and glare. QuadSight™ is the first quad-camera multi-spectral vision solution of its kind, driven by advanced and proven image processing algorithms. The system consists of two sets of stereoscopic infra-red and visible-light cameras that enable highly accurate and reliable obstacle detection for seamless 24/7 vision.
  • Eyes-On™. This solution uses advanced algorithms for accurate depth analysis and obstacle detection to provide a unique stereo vision Advanced Driver Assistance System (ADAS). It can detect all potential obstacles regardless of shape, form or material, including other vehicles, cyclists, pedestrians and animals. It has an accuracy and reliability of almost 100 percent and near zero false alerts.
  • Eye-Net™. This is a cellular-based accident prevention solution that is designed to provide real-time pre-collision alerts to vehicles and pedestrians. This proprietary system is deployed on smartphones and cloud-based servers operating on existing cellular networks, and it eliminates the need for additional designated hardware. Eye-Net™ is designed to provide a complementary layer of protection to advanced driver assistance systems and extends this protection to road users who are not in direct line of sight. It is optimally designed for both urban environments and high-speed scenarios to provide protection for the most vulnerable road users. On March 28, 2018, Foresight announced that it had completed a successful feasibility study of its Eye-Net™ accident prevention solution involving 120 users of Android and iOS cell phones located across Israel.

In 2017, Foresight sought more opportunities within the international market. The Company signed pilot agreements with three leading car manufacturers in China and completed pilot projects meeting all pre-defined requirements and criteria. In addition, FRSX completed a pilot project with Uniti Sweden.

Studies by the Insurance Institute for Highway Safety continue to emphasize the dramatic reduction in accidents and injury-related crashes reported when vehicles are equipped with collision avoidance systems. A recent study by the Institute states that the rate of single-vehicle, sideswipe and head-on crashes was 11 percent lower in vehicles with the warning systems. More importantly, the study shows collision avoidance technology cut the rates of injury crashes of the same type by 21 percent.

Foresight Autonomous Holdings, Inc. also holds a 32 percent interest in RailVision, a company that develops advanced systems for railway safety and maintenance. RailVision has successfully completed 13 tests in Israel, Germany, Italy and Switzerland in addition to a real-time system test with a European railway operator. Over the course of 2017, RailVision successfully completed rounds of financing totaling $5.8 million and started the process of licensing the system according to European standards.

Haim Siboni is the founder of Foresight and has served as the company’s chief executive officer and director since 2015. Siboni, a passionate entrepreneur, has an extensive background in the marketing and business management sectors in the fields of electronics, video, TV, multimedia, computerized systems, line and wireless telecommunication, design and development of systems and devices, including electro-optic radar systems. He is the founder and CEO of Magna B.S.P., Foresight’s major shareholder and a leading innovator in the field of homeland security surveillance solutions.

Foresight Autonomous Holdings Ltd. (FRSX), closed the day's trading session at $3.34, up 14.72%, on 881,753 volume with 3,342 trades. The average volume for the last 60 days is 25,975 and the stock's 52-week low/high is $2.44/$11.70.

Recent News

chart

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company"), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform solutions to the worldwide life sciences industry, today announced the conversion of an additional $7.24M of debt into equity, bringing the total amount of debt that has converted into equity over the past four weeks to over $13.6M.

Pressure BioSciences Inc. (OTCQB: PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed the day's trading session at $3.48, up 13.36%, on 1,067 volume with 7 trades. The average volume for the last 60 days is 1,119 and the stock's 52-week low/high is $0.70/$8.50.

Recent News

chart

Medical Cannabis Payment Solutions (REFG)

The QualityStocks Daily Newsletter would like to spotlight Medical Cannabis Payment Solutions (REFG).

Medical Cannabis Payment Solutions (OTC: REFG), a financial services company directed at the medical cannabis and banking industries, has been filling the gap for cannabis providers who lack bank support due to federal regulations by providing online banking solutions.

Medical Cannabis Payment Solutions (REFG), headquartered in Cheyenne, Wyoming, is a first-tier merchant processing cannabis industry pioneer, offering one of the first and only comprehensive card processing operations of its kind to serve the state-sanctioned medical marijuana industry. The company’s state of the art system, which also tracks sales and tax collection, and eliminates the need to deal in cash-only transactions.

Through its robust, closed-loop merchant processing system, the company’s unique “StateSourced” proprietary system enables authorized operation under FinCEN parameters and complies with all regulatory frameworks. StateSourced is tailored to deliver full-spectrum merchant processing services, providing the convenience of modern commercial card processing resources and making it the first operation of its kind geared to the legal cannabis industry.

StateSourced is not a prepaid or gift card, which is an important variable for merchants since standard banking institutions have not offered this form of payment processing to the legal cannabis industry. Federal law still considers marijuana illegal under the Controlled Substances Act, although 29 states and the District of Columbia have legalized the plant either for medicinal or recreational uses or both. This restriction has kept financial institutions at bay since most banks are federally insured and haven’t been inclined to venture into the nascent industry.

Medical Cannabis Payment Solutions is able to offer its StateSourced card on a state-by-state basis where the card can be used in purchasing product from a legal, authorized vendor, providing a much-needed option for consumers and businesses alike. In another first, the company is collaborating with First Bitcoin Capital Corporation to integrate First Bitcoin’s cryptocurrency ($Weed) with Medical Cannabis Payment Solutions’ StateSourced payment gateway. This collaboration will allow state-licensed marijuana establishments across the nation to accept both StateSourced debit cards and cryptocurrencies such as WeedCoin and Bitcoin.

Medical Cannabis Payment Solutions president and CEO Jeremy Roberts and his executive team are working with state lawmakers to introduce legislation in an effort to address the growing problems in banking for the medical cannabis industry. For companies in the emerging legal cannabis industry, where retail and non-retail transactions such as vendor payments and payroll are almost exclusively paid for with cash, the solutions offered by StateSourced can help businesses avoid the inherent risks associated with a cash-intensive sector. Medical Cannabis Payment Solutions has also signed its first StateSourced contract with a Las Vegas-based vertically integrated marijuana establishment.

“We’ve completed our transition from development stage to revenue stage,” says Roberts. “We have just started our business development efforts and the market is responding very well. We anticipate having many more, similar releases.”

Medical Cannabis Payment Solutions provides end-to-end management across multiple systems for medicinal marijuana operations. The company solves the fragmentation problem experienced by many of these rapidly growing companies by identifying tools that are important to dispensaries and customizing those tools to meet the specific needs of this unique industry.

Medical Cannabis Payment Solutions (REFG), closed the day's trading session at $0.046, up 7.48%, on 364,474 volume with 47 trades. The average volume for the last 60 days is 581,725 and the stock's 52-week low/high is $0.0161/$0.092.

Recent News

chart

Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

Net Element, Inc. (NASDAQ: NETE) (“Net Element” or the “Company”), a global technology and value-added solutions group that supports electronic payments acceptance in a multi-channel environment including point-of-sale (“POS”), e-commerce and mobile devices, announces the extension of its Netevia platform to include a smart solution for enabling secure vendor payments.

Net Element (NETE), is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce, and mobile devices. Net Element operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets. Internationally, Net Element’s strategy is to leverage its omni-channel platform to deliver flexible offerings to emerging markets with diverse banking, regulatory and demographic conditions. Net Element was ranked as one of the fastest growing companies in North America on Deloitte’s 2017 Technology Fast 500 ™ and South Florida Business Journal’s 2016 fastest growing technology companies.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. Net Element’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

In a partnership with Bunker Capital, Net Element has also launched a new blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

  • Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
  • Digital Provider – A leading provider of SMS messaging and mobile billing solutions.
  • Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
  • Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked No. 418 on Deloitte’s 2017 Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies. Net Element grew 190 percent. The company’s chief executive officer, Oleg Firer, credits the company’s progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

“The Deloitte 2017 North America Technology Fast 500 winners underscore the impact of technological innovation and world class customer service in driving growth, in a fiercely competitive environment,” said Sandra Shirai, vice chairman, Deloitte Consulting LLP and U.S. technology, media and telecommunications leader. “These companies are on the cutting edge, and are transforming the way we do business.”

Net Element’s suite of application performing interfaces (APIs) and connectors power commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Net Element’s corporate team is led by director and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jonathan New, CPA, and Steven Wolberg, who is the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations such as Digital Provider and Aptito to e-commerce and retail payment transaction processing brands like Payonline and United Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed the day's trading session at $7.85, up 0.26%, on 189,256 volume with 747 trades. The average volume for the last 60 days is 456,569 and the stock's 52-week low/high is $2.556/$33.51.

Recent News

chart

Earth Science Tech, Inc. (ETST)

The QualityStocks Daily Newsletter would like to spotlight Earth Science Tech, Inc. (ETST).

Earth Science Tech, Inc. (OTC: ETST) has established testing dates for three of its cannabinoid-based (CBD) products. Funded by a grant from Quebec, ETST is now prototyping three CBD patent formulas. A superfood edible is expected to be ready for 4Q2018. The company is scheduled to begin in vitro testing on its first batch of formulas in the summer of 2019, with a goal of demonstrating the superior antioxidant properties and anti-proliferative effects on breast cancer cells, it announced (http://cnw.fm/Qs2C4).

Earth Science Tech, Inc. (ETST) is an innovative biotechnology company operating in the fields of hemp cannabinoid (CBD), nutraceutical, pharmaceutical and medical device research and development. Earth Science Tech offers the highest purity and quality, full-spectrum, high-grade hemp CBD (cannabidiol) oil on the market. Made using the supercritical CO2 liquid extraction process, the company’s CBD oil is 100 percent natural and organic. Earth Science Tech has partnered with the University of Central Oklahoma and DV Biologics Laboratory to conduct research and development projects that scientifically support and advance the healthcare benefits of its high-grade hemp CBD oil.

Earth Science Tech Inc. currently has three wholly owned subsidiaries focused on developing its role as a world leader in the CBD space and expanding its work in the pharmaceutical and medical device sectors. These subsidiaries include:

  • Earth Science Pharma, Inc., which is committed to development of low cost, noninvasive diagnostic tools, medical devices, testing processes and vaccines for sexually transmitted infections and/or diseases. Earth Science Pharmaceutical CEO and chief science officer Michel Aubé is leading the company’s research and development efforts. The company’s first medical device, MSN-2, is a home kit designed for the detection of STIs, such as chlamydia, from a self-obtained gynecological specimen. Earth Science Pharma is working to develop and bring to market medical devices and vaccines that meet the specific needs of women.
  • Cannabis Therapeutics, Inc. (“CTI”), which is poised to take a leadership role in the development of new, leading-edge, cannabinoid-based pharmaceutical and nutraceutical products. CTI is invested in research and development to explore and harness the medicinal power of cannabidiol. The company holds a provisional application patent for a CBD product that is focused on developing treatments for breast and ovarian cancers.
  • KannaBidioiD (“KBD”) provides a wide variety of products geared toward the recreational space of cannabis. KBD’s unique Kanna and CBD formulation is sold and distributed in CBD-infused edibles and vapes/e-liquids products. Kanna and CBD synergistically enhance one another, providing optimal relaxation, an uplifting sensation, enhanced focus and the added benefit of assisting with nicotine reduction therapy.

Earth Science Tech celebrated a significant, developmental year during 2017 by sharing its achievements in a condensed end-of-year report. Among the report’s highlights are the implementation of a development plan for the coming three years, which includes expanding into Canada and opening new manufacturing and shipping facilities. Of particular interest is the acquisition of Canna Inno Laboratories Inc., a company headquartered in Montreal, Quebec, Canada, which gives Earth Science Tech access to Canadian government grants offered to innovators in the pharmaceutical industry. ETST has also launched development of proprietary prophylactic therapies utilizing cannabidiol (CBD) to treat various forms of breast cancer.

In October 2017, ETST announced it is cooperating with the Clinique SIDA Amité (AIDS Friendship Clinic) for a mini-clinical trial, the last trial needed before the MSN-2 device, designed for the detection of STIs, enters molecular diagnostic trials. And in November 2017, the company began pre-launch human trials on a new CBD formula to fight against the U.S. opioid epidemic. The new formula, expected to decrease cravings and the negative effects of withdrawal in addicts, is based on industrial hemp CBD mixed with a known natural ingredient proven to help increase dopamine levels. ETST’s medical devices will first be launched in Vietnam, Djibouti and Morocco while the company awaits regulatory permission to enter the North American market.

The company expects to up-list to the OTCQB in early 2018, which management believes will attract well-funded institutional investors and pave the way to becoming the next billion-dollar-in-capitalization company on the OTC markets. Other highlights include completion of the company’s Scientific Advisory Council with a team of recognized scientists, the launching of several CBD-infused edible products and entry into the medical devices market through collaborative partnerships.

Earth Science Tech has signed a collaborate agreement with Laboratories BNK Canada, a private laboratory that will conduct the clinical studies necessary for MSN-2 medical device-related services to meet regulatory requirements. ETST has confirmed the MSN-2 device’s ability to detect chlamydia, and is working to validate similar results for gonorrhea, both highly infectious diseases that often have permanent consequences for patients. ETST will also add testing for trichomoniasis and a complete body fluid panel to detect the different serotypes of the human papillomavirus (HPV) that causes cervical cancer. These additions will help the company create sales opportunities in the global market for diagnostic testing of STDs that Transparency Market Research has indicated will grow to $108 billion by 2019.

Cannabis Therapeutics is in the development stage of two cannabinoid-based pharmaceutical drugs and three cannabinoid-based nutraceutical products targeting a variety of ailments such as anxiety, depression, triple negative breast cancer, and fatty liver disease, among others. Research into the benefits of the non-psychoactive cannabinoid molecules found in the cannabis plant is supported by ETST’s International Application for Provisional Patent titled “Cannabidiol Compositions Including Mixtures and Uses Thereof,” which was filed on October 8, 2015. Cannabis Thera’s R&D efforts are concentrated on developing CBD-based drugs and nutraceutical products and in working to integrate the CBD molecule with existing generic drug molecules to create more efficient medications with fewer and less severe side effects. A report in Hemp Business Journal predicts the CBD consumer market will grow to $2.1 billion by 2020, while other industry experts expect an increase to almost $3 billion by 2021. A recent report by Statista projects the U.S. consumer market for cannabinoid-based pharmaceuticals could reach $50 billion by the year 2029.

The management team at Earth Science Tech brings decades of invaluable experience to the nutraceutical, dietary supplement field as well as the life sciences sectors. Nickolas S. Tabraue, who serves as the president, director and chief operating officer, is an industry veteran with extensive knowledge of supplements, retail management, customer service and sales expertise. He is joined by CEO and CSO Dr. Michel Aubé, a microbiologist whose scientific research in sexually transmitted infections, cancer and stem cell biology has been widely published in several prestigious medical journals. Sergio Castillo, chief marketing officer, and Gabriel Aviles, chief sales officer, bring a wealth of marketing and sales experience to Earth Science Tech, which is complemented by Issa El-Cheikh, Ph.D., and his 25 years in the international finance, accounting, planning and execution of large scale transactions in the public and private sectors.

Earth Science Tech’s products include CBD, a natural constituent of hemp oil derived from hemp stalk and seed. EST offers CBD in the form of vitamins, minerals, herbs, botanicals, personal care products, homeopathies, functional foods and other products delivered in such forms as capsules, tablets, soft gels, chewables, liquids, creams, sprays, powders and whole herbs. Earth Science products can be found at retail stores throughout the United States and are available for purchase through the internet.

Earth Science Tech, Inc. (ETST), closed the day's trading session at $0.70, even for the day, on 1,475 volume with 4 trades. The average volume for the last 60 days is 14,686 and the stock's 52-week low/high is $0.324/$1.62.

Recent News

chart

Sunniva, Inc. (CSE: SNN) (OTCQX: SNNVF)

The QualityStocks Daily Newsletter would like to spotlight Sunniva, Inc. (SNNVF).

Sunniva Inc. (CSE:SNN) (OTCQX:SNNVF) (“Sunniva” or the “Company”), a North American provider of cannabis products and services, is pleased to announce that its wholly-owned subsidiary CP Logistics, LLC’s Sun-Oil Facility has secured an additional extraction contract with Cali Gold, a leading and legacy California cannabis brand. Also today, CannabisNewsWire released a report on the company detailing the extraction contract and how the Sun-Oil Facility will provide Cali Gold with high quality, ultra-purified manufactured distilled oil products to be utilized within vaporization cartridges.

Sunniva, Inc. (CSE: SNN) (OTCQX: SNNVF) is a vertically integrated medical cannabis company operating in the world’s two largest cannabis markets – Canada and California – committed to delivering safe, consistent, high-quality products and services. Sunniva operates through its wholly owned subsidiaries: Sunniva Medical Inc., CP Logistics, LLC, Natural Health Service Ltd., and Full-Scale Distributors, LLC. Sunniva’s vision is to become the lowest cost, highest quality cannabis producer in the markets it serves by building large scale purpose-built cGMP-compliant greenhouses, offering best quality assurance with cannabis products free from pesticides, providing better patient and doctor access to cannabis education, and sourcing better therapeutic delivery devices.

The company is establishing sophisticated distribution channels, including Sunniva’s ownership of Natural Health Services cannabis clinics in Canada with over 95,000 active patients, to purchase the significant quantities of high quality Sunniva-branded and Sunniva private-labeled cannabis products.

Sunniva is an ancient English name which means, “Gift of the Sun.” Sunniva’s team of horticulturists, scientists and engineers is helping to set best practices for the industry, believing that sun-grown, solar-powered cultivation is the most sustainable and cost-effective way to grow high-quality, premium cannabis.

The Sunniva Family includes:

CP Logistics, LLC

Through its subsidiary, CP Logistics LLC, Sunniva is developing Sunniva Campus, a state-of-the-art, purpose-built greenhouse facility in Cathedral City, California. This modern purpose-built, agri-technology greenhouse will adhere to the Current Good Manufacturing Practice (cGMP) regulations that assure proper design, monitoring and control of manufacturing processes and facilities.

Phase 1 of the project includes a fully funded 325,000 square foot greenhouse capable of producing 60,000 kg per year of dry cannabis at capacity with operations commencing Q3 2018. Approximately 30 percent of initial total production will be converted into oils and extracts. Phase 2 is expected to increase the greenhouse by 165,000 square feet and grow production by about 40,000 kg per year.

These uniquely sealed greenhouses are designed to deploy custom, automation assembly line cultivation processes at a large scale. Energy consumption will be reduced while utilizing the energy of the sun and microclimatic controls to provide precise growing conditions. The greenhouse will recirculate air for more efficient climate control, and the company’s Integrated Pest Management System is designed to ensure every plant grown is certified clean and free of all contaminants and pesticides.

Sunniva Medical Inc.

Sunniva Medical Inc. is designing and preparing to break ground on the Sunniva Canada Campus encompassing 700,000 square feet of purpose-built cGMP greenhouse facilities in the Okanagan Valley, British Columbia. The total campus is expected to produce 100,000 kg of premium medical cannabis a year plus additional trim used for extraction. This facility will produce pesticide-free products and will convert trim to extracted products such as cannabis oil that can be used for drug delivery formats such as capsules, dissolvable strips, vaporization cartridges, tinctures and creams.

Sunniva and Canopy Growth Corporation (“Canopy Growth”) recently announced a large take or pay supply agreement. Under the terms of the agreement, Canopy Growth will purchase up to 45,000 kilograms of dried cannabis annually commencing Q1 2019, which includes the distribution of Sunniva branded products. Sunniva Medical is a late-stage applicant under Canada’s ACMPR and is in the final review stage of the process.

Natural Health Services Ltd.

Natural Health Services (“NHS”) owns and operates a network of eight medical clinics in Canada specializing in medical cannabis under the Access to Cannabis for Medical Purposes Regulations (“ACMPR”). NHS connects licensed producers to their 21 physicians and patients with its proprietary SPARK software which utilizes a software-as-a-service revenue model. To date, there are 27 integrated licensed producers utilizing the SPARK software.

In-house physicians specializing in the endocannabinoid system provide expert consultation, education and recommendations for targeted phytoceutical remedies and wellness plans to improve the quality of life for all patients. NHS enjoys a long-term relationship with patients due to the quality of its physician-patient experience. A rapidly expanding NHS cannabis clinic network serves 94,000 active patients in Canada. NHS has also initiated a pilot program with a national pharmacy chain to aggregate more patients.

Full-Scale Distributors, LLC

Full-Scale Distributors, LLC is an industry leading provider of custom, private-label vaporizers through its brand, Vapor Connoisseur. The company currently serves the needs of over 80 top brands in the North American marketplace. Vapor Connoisseur is recognized for its high quality and innovative therapeutic delivery devices. Products are tailored to client needs, ensuring both safety and reliability.

Sunniva’s highly experienced management team is building partnerships with leading scientists, universities and clinical trial groups to deliver proprietary cannabis formulations to a broad spectrum of health ailments and conditions. These global partners require cGMP-certified facilities for the processing and manufacturing of cannabis products. Sunniva is committed to providing safe, pesticide-free, high quality, reproducible cannabis medicines.

Leading Sunniva is co-founder, chairman and CEO Dr. Anthony (Tony) Holler. He is the former CEO and founder of ID Biomedical, which was acquired in 2005 for $1.7 billion by GlaxoSmithKline. He is also the former chairman of Corriente Resources Inc., which was sold for approximately $700 million to CRCC-Tongguan Investment Co. Holler is currently chairman of CRH Medical Corporation, a public company trading on the TSX and NYSE. His expertise includes strategic planning, mergers and acquisitions and financing with a singular focus on increasing shareholder value.

Holler is joined by co-founder Leith Pedersen, who serves as president of Sunniva. Pedersen is the former owner and CEO of Vida Wealth Management Bahamas and was a former investment advisor at Canaccord Wealth Management. He is a former partner and director at JF Mackie and Company, an independent brokerage firm in Calgary, Alberta, that managed capital in excess of $2 billion for high net worth clients. Pedersen’s expertise is in corporate strategy, financing and mergers and acquisitions.

Sunniva, Inc. (SNNVF), closed the day's trading session at $6.2201, off by 0.16%, on 31,520 volume with 98 trades. The average volume for the last 60 days is 36,208 and the stock's 52-week low/high is $5.86/$16.00.

Recent News

chart

Lithium Chile Inc. (TSX.V: LITH) (OTCQB: LTMCF)

The QualityStocks Daily Newsletter would like to spotlight Lithium Chile Inc. (LTMCF).

Three South American countries are responsible for the majority of the world’s lithium, whose demand is projected to double by 2025. In terms of sheer lithium output, it is a head-to-head battle between Argentina and Chile, and things are heating up. Companies such as Lithium Chile (TSX-V:LITH) (OTC:LTMCF) are poised to take advantage of the most intense mining industry-race of 2018.

Lithium Chile Inc. (TSX.V: LITH) (OTCQB: LTMCF), headquartered in Canada, is advancing one of the largest lithium-rich exploration portfolios in Chile consisting of more than 148,000 hectares covering sections of 13 salars or mineral salt flats and one laguna complex. The company’s wholly owned premier properties include 66 square kilometers on the Salar de Atacama, Chile’s largest mineral salt flat which hosts the world’s highest concentration of lithium brine production and is currently the source of about 35 percent of the world’s lithium production. Lithium Chile also owns a significant copper/gold/silver property portfolio consisting of 28,184 hectares over six different properties.

Lithium Chile’s portfolio in the heart of Chile’s lithium-rich salars includes Salar de Coipasa, Salar de Helados, Salar de Atacama, Salar de Turi Salar de Ollague and Salar de Talar. Surface and near surface salt and brine sampling programs on all properties has been completed. To date, samples of high-grade, near-surface lithium brines at each of these projects are showing excellent chemistry of lithium to potassium and lithium to magnesium ratios. Good chemistry is important as it reduces your overall cost of production. Recent geophysical surveys including T.E.M have been completed on 5 of 6 priority targets and data collected to date has been extremely encouraging.

Lithium Chile has identified multiple high-priority brine target areas at its Atacama and Ollague lithium project areas. These areas display the same geophysical characteristics as the lithium-rich aquifers at Salar de Atacama, home to the world’s largest and highest-grade lithium brine producers. Spanning an area of 1,200 square miles, Salar de Atacama is the world’s third largest salt flat behind Salinas Grandes in Argentina and El Salar de Uyuni in neighboring Bolivia. Exploration drilling and resource definition drilling for these target areas are planned for 2018.

“We are delighted with the discovery of such impressive drill target areas at Atacama and Ollague. The results also follow the recent discovery of a 60km2 target area at another of our top Chilean projects – Helados – where we hope to drill in the second quarter of 2018,” stated President and CEO Steve Cochrane. “We have an aggressive multi-project drill program planned for this year, which includes all three of these exciting projects and we look forward to sharing drill results as they come through.”

Global demand for lithium-ion batteries is expected to surpass US$53 billion by 2024 as governments around the world aggressively seek to ban gas-powered vehicles and major automakers invest billions in new technology and electric vehicles powered by lithium-ion batteries. Chile’s mining-friendly jurisdiction offers Lithium Chile a clear, streamlined permitting process that significantly lowers the cost of lithium production to around $1,800/ton as compared to Australia’s $5,000/ton.

Lithium Chile is led by an experienced team with strong Chilean connections. Cochrane’s 36 years of investment industry experience have primarily been focused on the mining sector. During this time, he raised more than US$500 million for a variety of small cap public companies in various businesses and industry sectors including mining.

Terry Walker, P.Geol., vice president of exploration and chief geologist, is a highly experienced geologist. He has spent over 25 years in Chile’s mining industry and is well connected throughout the sector. Walker is co-founder of GeoServicios Piedra Dorada, an exploration and development services company focused on Latin America. He is a Qualified Person for the North American and Australian stock exchanges.

Lithium Chile is well funded and driven by a top-tier team with more than 100 years of combined experience in financing, mining exploration and development in the natural resources sector.

Lithium Chile Inc. (LTMCF), closed the day's trading session at $0.7472, off by 7.92%, on 175,406 volume with 127 trades. The average volume for the last 60 days is 11,754 and the stock's 52-week low/high is $0.6587/$0.9614.

Recent News

chart

The Green Organic Dutchman (TSX: TGOD)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (TSX: TGOD).

When The Green Organic Dutchman (TSX: TGOD) came public last month in what was arguably the most highly anticipated IPOs in Canada so far this year, things went well with a record-setting raise of $132 million+. TGOD’s wholly-owned subsidiary, Medican Organic Inc., received its cultivation license from Health Canada for its breeding facility in Salaberry-de-Valleyfield, Quebec. Also today, CannabisNewsWire released a report on the company detailing how TGOD has announced a global strategic launch into the beverage industry. The company’s veteran management team’s plan is to now put their vast experience to work creating a strategic path into the cannabis beverage market (http://cnw.fm/I3X1b).

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (TSX: TGOD), closed the day's trading session at $6.77, off by 10.33%, 175,406 volume with 127 trades. The average volume for the last 60 days is 11,754 and the stock's 52-week low/high is $0.6587/$0.9614.

Recent News

chart

Consorteum Holdings, Inc. (CSRH)

The QualityStocks Daily Newsletter would like to spotlight Consorteum Holdings, Inc. (CSRH).

As a mobile solutions and software development company, Consorteum Holdings, Inc. (OTC: CSRH) is focused on mobile device digital offerings delivery. Consorteum further provides mobile payment solutions and products through its mix of direct offerings, license agreements and joint business agreements. Following a multi-year transition, the company has moved from transaction management with a focus on processing solutions and payment processing alongside financial transaction markets to one that focuses on deepening the company’s commitment to delivering innovative solutions via multiple business verticals (http://nnw.fm/ZBH2v).

Consorteum Holdings, Inc. (CSRH) is a software development and mobile solutions company focused on the delivery of digital offerings to mobile devices. The company provides mobile offerings, delivery of mobile content, mobile payments solutions and products through a mix of direct offerings, partnerships, license agreements and joint venture arrangements. A multi-year transition from a transaction management company focused on transaction processing solutions and products for the payment processing and financial transaction markets to multiple business verticals deepens the company’s commitment to deliver innovating solutions to end users who are using smart handset devices in radical new ways.

Consorteum Holdings, utilizing its Universal Mobile Interface™ (“UMI”) solution, offers opportunities in numerous markets with its capacity to support fully regulated, regionally compliant financial and social transactions via web and mobile. The company’s UMI technology has the capacity to provide solutions in FinTech, data analytics, secure payment processing, compliance lead transaction management and various digital social event sectors. The UMI platform allows cross operating system development to support all mobile devices while addressing the complex and highly regulated needs of the mobile FinTech industry.

Led by the development team at Consorteum’s wholly owned subsidiary 359 Mobile Inc., the Company has created an end-to-end FinTech solution utilizing the company’s UMI technology platform. Current mobile application and transaction solutions are plagued by poor experiences. Because UMI’s technology platform is designed to work across innovative payment, experience and product solutions, 359 Mobile believes there are both direct and partnership opportunities for the 359 Mobile UMI solution.

Consorteum’s primary sales and marketing strategy is focused on enabling and delivering solutions to the global mobile FinTech market with an emphasis initially on mobile gaming. The trend towards increased mobile gambling supports the need for a mobile platform such as the UMI to meet existing and new compliance regulations for the online gambling industry. The online gambling market is projected to double to nearly $1 trillion by 2021, according to a study by Juniper Research, with the majority of growth in this sector attributed to mobile devices. Consorteum’s management team believes there are fresh opportunities in this sector such as Mobile Marketing Services providing one-to-one marketing experiences for consumers; offering real-time services to Mobile Sports Book operators; and providing fixed odds betting solutions as well as social-based transactional solutions.

Consorteum’s management team includes Chairman and CEO Craig A. Fielding, a co-founder of the company with extensive experience in technology, programming and large system building; and Chief Operating Officer Patrick Shuster, who has over 25 years of business experience in sales, engineering, operations and marketing for the telecommunications industry. They are joined by John Osborne, SVP of Technology of ThreeFiftyNine Inc., an innovator in embedded systems hardware and software design; Patrick Doran, SVP of business development and marketing with over 30 years of diversified experience in major corporations as well as early stage companies; and Glenn Charlesworth, VP of Accounting, a seasoned executive with a solid track record in financial reporting, strategic planning, general management and operations, finance, start-up situations, and cash flow challenged operations.

Consorteum Holdings is committed to bridging the mobile divide by providing mobile connectivity, secure transactional processing and social connectivity solutions for both cloud and hosted based offerings in multiple business sectors.

Consorteum Holdings, Inc. (CSRH), closed the day's trading session at $0.0023, off by 14.81%, on 11,232,800 volume with 37 trades. The average volume for the last 60 days is 11,119,995 and the stock's 52-week low/high is $0.0005/$0.0085.

Recent News

chart

Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P)

The QualityStocks Daily Newsletter would like to spotlight Liberty Leaf Holdings Ltd. (LIBFF).

Liberty Leaf Holdings Ltd. (CSE: LIB) (OTCQB: LIBFF) (FSE: HN3P) is a publicly traded Canadian-based company with strategic investments in businesses that are established, revenue- producing players in the medicinal and recreational cannabis market. Liberty Leaf’s focus is to build and support a diversified portfolio of cannabis-sector businesses, including those involved in the cultivation and processing of legal medicinal and recreational cannabis, value-added CBD/THC pet products, and supply-chain products for this dynamic and fast-growing sector. Liberty Leaf provides funding, management, HR resources and marketing expertise to help companies thrive and accelerate growth.

Liberty Leaf’s leading investments to date include:

  • North Road Ventures – An emerging end-to-end distributor of cultivated and manufactured cannabis products to licensed legal retailers. North Road has updated its application for an Access to Cannabis for Medical Purposes Regulations (ACMPR) license to be distribution/sales-focused, making the company unique in the crowded field of other cultivation-based applicants. This forward-thinking initiative will help fulfill the anticipated increase in Canada’s recreational cannabis space once legalization takes effect in mid-2018. The submission includes a boost in product-vault capacity that will result in a five-fold increase in products available for distribution. Cannabidiol (CBD)-oil products are expected to account for 50 percent or more of projected sales.
  • Just Kush Enterprises – Liberty Leaf holds a 60 percent interest in Just Kush, a cultivator of premium, proprietary cannabis strains selected for different levels of CBDs and THCs. Just Kush’s cultivation facility is located near Oliver, British Columbia, and it currently controls a facility which holds a Medical Marihuana Access Regulations (MMAR) license. The company is also a late-stage applicant for an ACMPR license (Access to Cannabis for Medical Purposes Regulations), which will enable Just Kush to produce cannabis for the medicinal and recreational market.

Liberty Leaf is also an active partner with the following companies:

  • ESEV R&D – A privately owned, medical marijuana research and development company based in New York with clinical laboratories located in Israel. ESEV R&D, in collaboration with a leading clinical research organization in Israel, has launched a one-of-a-kind service for North American medical cannabis companies to organize and oversee clinical trials seeking to demonstrate the efficacy of medical cannabis products for specific medical conditions. Liberty Leaf has a three-year collaborative agreement with ESEV. Under that agreement, ESEV is researching the efficacy of CBDs in pets, with the 1st formulation trial targeting canine osteoarthritis, a medical condition that includes: hip dysplasia; elbow dysplasia; and hind-knee, also known as stifle, degenerative joint disease (DJD).
  • Blox Labs Inc. – A boutique technology development company focused on creating best-in-class software solutions driven by emerging trends in blockchain, smart contracts and decentralized application technologies. Liberty Leaf and Blox Labs are developing “cannaBLOX,” a blockchain-based smart contract supply chain management platform for the legalized cannabis industry. The cannaBLOX blockchain software will aim to ease and obliterate logistical bottlenecks, ensure product safety and quality of supply, minimize fraud and potential criminal activity, and assist with taxation and regulatory compliance across various levels of government within the legalized cannabis marketplace. To date, preliminary framework and analysis required for a cannaBLOX Whitepaper has been completed and a development team that specializes in blockchain and decentralized application technologies, including omni-language development in Ethereum and NEO, is now working on the project.

The company’s management team is led by President and Director William Rascan who has 25-plus years in the investment brokerage industry, most recently as a partner, senior investment advisor with Northern Securities. Rascan’s business experience ranges from active international trading clients to raising capital for junior mining companies on the TSX Venture Exchange.

Rascan is joined by CFO Jamie Robinson, a chartered accountant who specializes in accounting, auditing, and financial reporting under both IFRS and ASPE. Prior to joining Liberty Leaf, Robinson worked at Deloitte as a manager focused on publicly listed and private company audits, business review, performance enhancement engagements and restructuring proceedings.

Steven Feldman, who has more than 25 years of experience in the capital markets and was part of the original management team of SouthGobi Resources; and Doug Macdonell, a retired RCMP officer and recognized expert in the field of cannabis and cultivation, serve as company directors. Dr. Robert Jackman, who has worked closely with multiple clients in the medical cannabis and Natural and Non-prescription Health Products (NNHP) industries in North America, was recently appointed as scientific project manager/fulfillment.

Liberty Leaf’s advisory board includes international lawyer, writer and speaker Robert W.E. Laurie; Barinder Rasode, who currently serves as CEO of the National Institute for Cannabis Health & Education (NICHE); and Dr. Mary C. Fitzpatrick, B.S., D.V.M., whose primary focus is on helping companion animals live pain free in their senior years.

Liberty Leaf Holdings Ltd. (LIBFF), closed the day's trading session at $0.2093, off by 5.48%, on 15,751 volume with 7 trades. The average volume for the last 60 days is 70,214 and the stock's 52-week low/high is $0.0091/$0.8074.

Recent News

chart

TMSR Holding Company (NASDAQ: TMSR)

The QualityStocks Daily Newsletter would like to spotlight TMSR Holding Company (TMSR).

TMSR Holding Company (NASDAQ: TMSR), together with its subsidiaries, is a recognized leader in the research, development, production and sale of solid waste recycling systems and zero emissions process systems, for the industrial and mining sectors in the People’s Republic of China. The company operates through its wholly owned business divisions: Shengrong Environmental and Wuhan HOST Coating Materials.

TMSR’s Shengrong subsidiary designs, builds, sells and services customized solid waste recycling systems and equipment for some of the largest industries in China. The company provides customers full-service, tailor-made systems from conceptual design to planning, production, modernization, optimization, assembly, start-up, conversions, disassembly, maintenance and servicing of components to complete zero emissions solid waste recycling and process systems.

Utilizing what management believed to be the world’s most advanced technologies of physical magnetic industrial solid waste recovery, Shengrong can process a variety of industrial solid waste materials and is able to extract valuable metal byproducts from the waste without generating any chemical pollution. Shengrong’s patented equipment can process aluminum slag, copper mine tailings, iron mine tailings, red mud manganese tailings, and molybdenum tailings among many others. Unlike traditional chemical-based recovery methods, the company extracts resalable metals from the waste without generating any pollution. The residues are processed to manufacture high-quality construction materials, turning polluted solid waste into valuable industrial materials with zero discharge.

Industrial solid waste recycling and heavy metal removal are significant worldwide technical, financial and environmental issues. Through Shengrong, TMSR is addressing this profound unmet market need by delivering end users a clean alternative to traditional waste disposal. The company intends to leverage these serious unmet needs, expand its patented industrial waste recycling systems to broad international markets, and provide global industrial and mining businesses cost-effective, patented green technology platforms that create new-found revenue streams for end users.

Through Shengrong, TMSR owns two U.S. patents and five patents granted by the Peoples Republic of China, including four invention patents and two utility model patents. The company’s research and development efforts have achieved technological advancements that allow end users to eliminate pollutant discharge as well as generate new revenue streams by selling valuable byproducts extracted from industrial waste.

TMSR subsidiary, Wuhan HOST Coating Materials, is the largest manufacturer of inorganic Zinc-rich resin and one-component epoxy Zinc-rich resin in China. Established in 2010, Wuhan HOST is a leader in the research and development, production and sale of Zinc-rich coating materials throughout the PRC and has a broad customer base that includes some of the foremost enterprises in major industries such as electricity, metallurgy, machinery, chemicals, bridge and shipping. TMSR completed the acquisition of 100% equity interest in Wuhan HOST Coating Materials on May 1, 2018.

Notably, TMSR first went public as JM Global Holding Company, a Special Purpose Acquisition Company (SPAC) formed to effect a merger, asset acquisition or other business combination that had exceptional growth potential. After reviewing over 50 potential targets and completing due diligence and third party analysis, JM Global identified China Sunlong Environmental Technology Inc. and its wholly owned subsidiaries as the acquisition target. Upon closing the business combination, the company was re-named TMSR Holding Company Ltd.

Demand for TMSR’s products is expected to grow significantly due to Chinese policies that encourage mining and manufacturing companies to adopt “green” technology. Approximately 3 billion tons of industrial solid waste were generated annually in China between 2011 through 2015.  Currently, 95% of industrial solid waste in China is stored in special facilities and sites; however, the cost of storage, disposal and incineration of industrial solid wastes is high. TMSR is focused on exploiting this unmet need, providing end users in the solid waste recycling markets a clean alternative to traditional waste disposal, significantly reducing solid waste discharge into the environment and enabling end users to extract value from industrial waste materials.

TMSR Holding Company (TMSR), closed the day's trading session at $7.47, off by 6.04%, on 4,100 volume with 28 trades. The average volume for the last 60 days is 143 and the stock's 52-week low/high is $7.21/$10.50.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.